Nanosponge drug treatment 3-5 times more effective than jabs

James Street — Thu, 03 Jun 2010 18:22:20 +0000

2010-06-03 05:30:00

Scientists have found that a delivery system based on a technique called nanosponge is three to five times more effective at reducing tumor growth than direct injection.

“Effective targeted drug delivery systems have been a dream for a long time now but it has been largely frustrated by the complex chemistry that is involved,” says Eva Harth, assistant professor of chemistry at Vanderbilt, who developed the nanosponge delivery system.

“We have taken a significant step toward overcoming these obstacles.”

Tiny sponges about the size of a virus are filled with a drug and attached with special chemical “linkers” that bond preferentially to a feature found only on the surface of tumor cells and then injected into the body.

The tiny sponges circulate around the body until they encounter the surface of a tumor cell where they stick on the surface (or are sucked into the cell) and begin releasing their potent cargo in a controllable and predictable fashion.

The advantages are two fold – the drug instead of traversing through the body is delivered exactly at the tumour and is thus, more effective. And because smaller amounts of the drug come into contact with healthy tissue, there are fewer harmful side effects.

Another major advantage is that the nanosponge particles are soluble in water.

“We call the material nanosponge, but it is really more like a three-dimensional network or scaffold,” says Harth.

“Predictable release is one of the major advantages of this system compared to other nanoparticle delivery systems under development,” Harth adds.

Also, the ability to control the size of the nanosponge is important because research has shown that drug delivery systems work best when they are smaller than 100 nanometers.

Simplicity is yet another boon. The researchers have developed simple, high-yield “click chemistry” methods for making the nanosponge particles and for attaching the linkers, which are made from peptides, relatively small biological molecules built by linking amino acids.

The drug used for the animal studies was paclitaxel (the generic name of the drug Taxol) that is used in cancer chemotherapy. The researchers recorded the response of two different tumor types – slow-growing human breast cancer and fast-acting mouse glioma – to single injections. In both cases they found that it increased the death of cancer cells and delayed tumor growth “in a manner superior to know chemotherapy approaches.”

The next step is to see if the nanosponge system can stop and reverse tumor growth.

The paper is published in the June 1 issue of the journal Cancer Research. (ANI)

Bone implants that support and release chemotherapeutical agents in ciclodextrin nanocapsule

James Street — Tue, 16 Mar 2010 05:17:43 +0000

15. March 2010 06:35

For the localized treatment of tumors

Bone implants with the ability to carry chemotherapeutical drugs in conception in CICECO

Chemotherapy, followed by the surgical removal of the affected tissue is the treatment usually adapted to bone tumors. An implant which can fill the areas of subtraction, while releasing chemotherapeutical agents locally, in a controlled manner, during the treatment period, is the aim of a research led by the Research Centre in Ceramic Material and Composites (CICECO/UA). In these experiences, specialists are using potential “anti-tumor” drugs coated by nanocapsules.

The osteosarcoma is the most common malignant primary bone tumor. Its major incidence is in children and youngsters and usually involves the amputation of arms and legs. The treatment for this type of tumor implies chemotherapy, followed by the surgical removal of the affected tissue with a safety area, in order to avoid the tumor’s reappearance. This area is then filled with a bone or synthetic biomaterial implant.

Considering how important it is to avoid repeating new chemo or radiotherapy treatments in these cases when neutralizing possible residual focus, 11 researchers from the Universities of Aveiro and Coimbra intend to develop an implant which can contain chemotherapeutical agents of specific ranges of action, and also release these components in a controlled manner for a specific and adequate period of time.

“The bone implants we are studying will serve as a support and releasing agent of capsulated drugs in a ciclodextrin nanocapsule. We are currently experimenting with an active molecule with anti-cancer properties specifically directed to osteosarcomas. Nevertheless, it is intended to broaden its application to other types of cancer“.

For this person, and as explained by Prof. Rui Correia, project coordinator, there is the need to proceed with the study of its mechanic and biological characteristics. “When we develop projects for these purposes, we must bear in mind their mechanic resistance, as well as other characteristics which must be taken in consideration when performing its implant in the bone. In this specific case, we are working with porous supports that contain a silica gel, manipulated to function both as a nanocapsule deposit and releaser. Its physical form will vary according to the bone area to fill.

The gel matrix will receive the anti-tumor compost (cisplatin and metallic composts), capsulated at a molecular level with ciclodextrin, coloured gello capsules which are nothing more and nothing less that sugar rings.

Prof. Ana Gil explains this innovative technique:

“A subgroup within our team, lead by researcher Susana Braga, is by the one hand, developing new metallic composts with a therapeutic potential and, by the other hand, promoting its capsulation in ciclodextrins. The use of the ciclodextrin on the coating of the medicinal molecule increases the efficiency of the drug and reduces the necessary amount. To work at a nanometric scale allows us to improve the properties, both concerning its solubility and its range of activity, allowing us to make it more specific”.

The nanocapsule protects the therapeutic agent from the contact with proteins which are irrelevant to the treatment and makes its located application simpler. The use of ciclodextrins as nanocapsules should protect the organism from the expected high toxicity of the new agents to the healthy cells.

This project, financed by the foundation for the Science and Technology, also presents an innovative aspect in what concerns the study of the metabolic effects of the new compounds (capsulated or not) on the human osteosarcoma cells, as explained by the researcher: “It is important to know the response of the cancer cells to the drugs, in order to be able to adjust and adapt the drug’s nature and dosage, for an effective treatment. These studies use the spectroscopy of the RMN- Magnetic Nuclear Resonance in the characterization of the cells’ metabolic profile and the application of adequate statistic treatments, which help identifying specific metabolic changes and their relation with the patterns of cellular death”.

With the drug in nanocapsules, there will be two types of implants to choose from: permanent titanium and biodegradable (for regenerative purposes) implants. The differences between these two are clarified by Prof. Rui Correia: “The porous supports which will allow the introduction of a chemic component in the organism are conceived from two types of biomaterials: a bio-stable one (non-degradable and biocompatible) and a polymeric, with biodegradable characteristics. The first one will be used in cases where there is a lack of ability to regenerate the bone tissue and the second in situations where there is the probability of a full natural recovery of the bone. In this last case the implant will be absorbed and progressively replaced by the natural bone”.

Besides the microstructural analysis, the researchers are proceeding with mechanic, physics and chemistry and in vitro rehearsals. There will also be performed metabolomics essays with cellular cultures which are subjected to the therapeutic agents, either molecularly encapsulated or not.

SOURCE Research Centre in Ceramic Material and Composites

Defeat Osteosarcoma » nanotechnology

Nanosponge drug treatment 3-5 times more effective than jabs

Bone implants that support and release chemotherapeutical agents in ciclodextrin nanocapsule